公开(公告)号：US20200181127A1

公开(公告)日：2020-06-11

申请号：US16793441

申请日：2020-02-18

Applicant: Pfizer Inc.

Inventor： Markus Boehm ,  Shawn Cabral ,  Matthew S. Dowling ,  Kentaro Futatsugi ,  Kim Huard ,  Esther Cheng Yin Lee ,  Allyn T. Londregan ,  Jana Polivkova ,  David A. Price ,  Qifang Li

IPC: C07D405/14 ,  C07D409/14 ,  A61K45/06 ,  A61K31/506 ,  C07D401/14

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

公开(公告)号：US20190382384A1

公开(公告)日：2019-12-19

申请号：US16436311

申请日：2019-06-10

Applicant: Pfizer Inc.

Inventor： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  David James Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Yajing Lian ,  Chris Limberakis ,  Allyn T. Londregan ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC: C07D405/12 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14 ,  C07C53/06 ,  C07C53/10 ,  C07C215/40

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20190106412A1

公开(公告)日：2019-04-11

申请号：US16211283

申请日：2018-12-06

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D403/14 ,  C07D403/04 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20180170908A1

公开(公告)日：2018-06-21

申请号：US15839901

申请日：2017-12-13

Applicant: Pfizer Inc.

Inventor： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC: C07D401/14 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14 ,  A61P3/10 ,  A61P25/28 ,  A61P25/02 ,  A61P13/12 ,  A61P43/00 ,  A61P3/04 ,  A61P1/16 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P19/06 ,  A61P15/10 ,  A61P17/06 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/30

CPC classification number: C07D401/14 ,  A61K31/4545 ,  A61K31/496 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.